Peer

Genetic architecture study of rheumatoid arthritis and juvenile idiopathic arthritis

Jun Jia^{1,*}, Junyi Li^{2,*}, Xueming Yao², YuHang Zhang³, Xiaohao Yang³, Ping Wang², Qianghua Xia², Hakon Hakonarson^{4,5,6} and Jin Li²

¹ Department of Surgery of Foot and Ankle, Tianjin Hospital, Tianjin, China

² Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin, China

- ³ Tianjin University of Traditional Chinese Medicine, Tianjin, China
- ⁴ Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America
- ⁵ Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, United States of America
- ⁶ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America

These authors contributed equally to this work.

ABSTRACT

Background. Rheumatoid arthritis and juvenile idiopathic arthritis are two types of autoimmune diseases with inflammation at the joints, occurring to adults and children respectively. There are phenotypic overlaps between these two types of diseases, despite the age difference in patient groups.

Methods. To systematically compare the genetic architecture of them, we conducted analyses at gene and pathway levels and constructed protein-protein-interaction network based on summary statistics of genome-wide association studies of these two diseases. We examined their difference and similarity at each level.

Results. We observed extensive overlap in significant SNPs and genes at the human leukocyte antigen region. In addition, several SNPs in other regions of the human genome were also significantly associated with both diseases. We found significantly associated genes enriched in 32 pathways shared by both diseases. Excluding genes in the human leukocyte antigen region, significant enrichment is present for pathways like interleukin-27 pathway and NO2-dependent interleukin-12 pathway in natural killer cells.

Discussion. The identification of commonly associated genes and pathways may help in finding population at risk for both diseases, as well as shed light on repositioning and designing drugs for both diseases.

Subjects Bioinformatics, Genomics, Allergy and Clinical Immunology, Rheumatology, Medical Genetics

Keywords Juvenile idiopathic arthritis, Rheumatoid arthritis, Genome-wide association studies, Genetic architecture comparison, Pathway enrichment

INTRODUCTION

Rheumatoid arthritis (RA) is a symmetric polyarticular arthritis that primarily affects the small diarthrodial joints of the hands and feet, while juvenile idiopathic arthritis (JIA) is caused by unknown etiology and persists at least 6 weeks in children under the age of

Submitted 6 June 2019 Accepted 18 November 2019 Published 15 January 2020

Corresponding authors Qianghua Xia, qhxia@tmu.edu.cn Jin Li, jli01@tmu.edu.cn

Academic editor David Meyre

Additional Information and Declarations can be found on page 10

DOI 10.7717/peerj.8234

Copyright 2020 Jia et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

16, which does not contain other known conditions (*Firestein, 2003; Prakken, Albani & Martini, 2011*). The prevalence rate of RA varies from 0.41 to 0.54% from 2004 to 2014 based on US administrative health insurance claims databases (*Hunter et al., 2017*), which is observably greater than the prevalence rate of JIA ranging from 0.0038 to 0.40% according to a systematic literature review including 29 articles (*Thierry et al., 2014*).

Phenotypically, RA and JIA are similar in some aspects. They show some common symptoms and physical signs such as joint pain and swelling, limited joint mobility and deformity, morning stiffness, elevated rheumatoid factor, fever, etc. Some of the subtypes of JIA, such as polyarticular JIA, are particularly similar to RA. However, with distinct clinical and pathological features of these two diseases being noted, they have been defined as separate diseases by International League of Associations for Rheumatology (*Petty et al., 2004*). In particular, JIA is heterogeneous with variable clinical presentation and outcome. It has been classified into seven subtypes, including oligoarticular JIA (persistent/ extended), polyarticular JIA with negative rheumatoid factor (RF), polyarticular JIA with positive RF, psoriatic JIA, enthesitis related arthritis, systemic JIA and undifferentiated JIA (*Nigrovic, Raychaudhuri & Thompson, 2018*). RA is more homogeneous but with a poorer outcome.

It has long been recognized that both RA and JIA are related to autoimmune and inflammatory disorders (Ravelli & Martini, 2007; Scott, Wolfe & Huizinga, 2010). Population-based heritability estimates for RA and JIA are both 60% approximately (Macgregor et al., 2000; Prahalad, 2006). Single-nucleotide polymorphism (SNP)-based heritability for RA has been reported to be around 50% (Speed & Balding, 2014; Speed et al., 2012), slightly lower than that of JIA estimated to be 73% (Li et al., 2015b). Certain alleles in the HLA region are strong genetic predisposition factors for RA and JIA. It has been reported that for both RA and JIA, the odds ratio of HLA region is about 2.8, while that of most non-HLA loci is only 1.1 to 1.4. (Nigrovic, Raychaudhuri & Thompson, 2018; Hersh & Prahalad, 2015; Viatte, Plant & Raychaudhuri, 2013) The genetic predisposition of JIA is attributable to HLA class II molecules (HLA-DRB1, HLA-DPB1), HLA class I molecules and non-HLA genes. The clinical presentation of RF-positive JIA resembles that of RA, and they share the HLA-DRB1 epitope (De Silvestri et al., 2017; Hinks et al., 2018). The HLA-DRB1*04 confers a protective role in JIA before the age of 6, while it renders an increased risk of RA (Nigrovic, Raychaudhuri & Thompson, 2018). The immunopathogenesis of RA has become clear in recent years, but the pathogenesis of JIA remains unknown (*Firestein* & McInnes, 2017; Mellins, Macaubas & Grom, 2011).

With the rapid development of genomic technology, a large number of genetic variants associated with RA or JIA have been identified. To date, genome-wide association studies (GWASs) have identified a large number of variants associated with RA and JIA respectively. A total of 789 RA-associated variants from 52 studies and 129 JIA-associated variants from 11 studies have been reported in GWAS Catalog (association testing *P*-value $<1 \times 10^{-5}$) (*Buniello et al., 2019*), including 101 loci associated with RA and around 30 loci associated with JIA at genome-wide significant level. We aimed to compare the genetic architecture of RA and JIA at multiple levels systematically.

In this study, we conducted gene, pathway and network analyses of RA and JIA using robust and computational efficient methods based on their summary GWAS statistics. We

compared genetic difference and similarity between RA and JIA, identified their shared genetic signature. Significant overlap in genes and pathways were observed between these two diseases.

MATERIALS AND METHODS

Data collection

RA genetic loci information came from GWAS summary statistics of a trans-ethnic study (*Okada et al., 2014*) including a total of 29,880 RA cases and 73,758 controls of European and Asian ancestries. Summary statistics was downloaded from GWAS catalog (https://www.ebi.ac.uk/gwas/) (*Buniello et al., 2019*). All RA patients met the RA diagnostic criteria established by the American College of Rheumatology in 1987 (*Arnett et al., 1988*), or were confirmed by a professional rheumatologist (*Okada et al., 2014*).

JIA genetic loci information came from two resources. First, summary statistics of our previous GWAS on JIA (*Finkel et al., 2016*) was included in the current study. Our JIA GWAS is composed of discovery and replication cohorts with 1166 JIA cases and 9500 unrelated controls of European ancestry totally. Summary statistics of meta-analysis on the discovery and replication cohorts were used in our current study. Second, JIA variants revealed in published GWASs (*Behrens et al., 2008*; *Cobb et al., 2014*; *Finkel et al., 2016*; *Hinks et al., 2009*; *Hinks et al., 2013*; *Li et al., 2015a*; *Ombrello et al., 2017*; *Thompson et al., 2012*) were extracted from GWAS catalog (*Buniello et al., 2019*).

Gene-based association analysis

A gene-based association analysis for RA and JIA was performed using *fastBAT* method (*Bakshi et al., 2016*) implemented in GCTA v1.91.7 (*Yang et al., 2011*) respectively, based on GWAS summary statistics of RA or JIA and linkage disequilibrium (LD) information from EUR population in the 1000 Genomes Project (*The Genomes Project Consortium et al., 2015*). Each gene region was defined as its transcript region and 50kb upstream/downstream, and the threshold for LD pruning was set to r²-value >0.9, following the default setting of *fastBAT*. The gene list of human genome used by *fastBAT* method contains 24765 annotated genes (*Bakshi et al., 2016*), thus the genome-wide significant threshold for gene based tests was set at $0.05/24765 = 2 \times 10^{-6}$. JIA SNPs in GWAS catalog was also mapped to genes according to its report (*Buniello et al., 2019*).

Protein-protein interaction network and pathway enrichment analyses

Competitive pathway enrichment analysis and protein-protein interaction (PPI) network visualization analysis were both performed using GWAS summary-level data by GSA-SNP2 (https://sites.google.com/view/gsasnp2) (*Yoon et al., 2018*). The LD information in the European population from the 1000 Genomes Project (*The Genomes Project Consortium et al., 2015*) was used to reduce false positives by combining highly correlated adjoining genes. Each gene region was defined as its transcript region and 20 kb upstream/downstream, as the default setting of GSA-SNP2. Gene-set database used for pathway construction were *C2(curated gene sets)CP(canonical pathways)v5.2*, which is a collection of online pathway

databases such as BioCarta (http://software.broadinstitute.org/gsea/msigdb/genesets.jsp? collection=CP:BIOCARTA) (*Nishimura*, 2001), KEGG (https://www.genome.jp/kegg/) (*Kanehisa et al.*, 2017; *Kanehisa & Goto*, 2000; *Kanehisa et al.*, 2019), Reactome (https: //reactome.org/) (*Fabregat et al.*, 2018) and PID (*Schaefer et al.*, 2009) by Molecular Signatures Database (MSigDB) (http://software.broadinstitute.org/gsea/msigdb) (*Liberzon et al.*, 2015; *Liberzon et al.*, 2011; *Subramanian et al.*, 2005). The network data resource was the STRING database (https://string-db.org/) (*Szklarczyk et al.*, 2015). Multiple-testing adjustment was performed and Q-value < 0.05 was set as the significance threshold. Global visual networks were constructed at a threshold of gene-score < 0.005 and Q-value < 0.05.

RESULTS

SNP-level comparison

A total of 26,285 SNPs (Table S1) in RA study and 105 SNPs (Tables S2, S3) in JIA study reached genome-wide significance threshold *P*-value $<5 \times 10^{-8}$, and these two diseases shared 47 significant SNPs. Among these SNPs, 37 were located in the human leukocyte antigen (HLA) region on chromosome 6. The rest 10 SNPs were located in or close to 9 genes (Table 1). Interestingly, 8 SNPs located in the HLA region showed opposite direction of effects, which meant risk allele of JIA could be protective allele for RA and vice versa.

Gene-based comparison

To increase statistical power and to consider the combined effects of SNPs in genes, we conducted gene-disease association analyses, based on SNP-level summary statistics and taking into account of LD between SNPs. Several methods have been developed for computing gene-level associations based on SNP-level summary statistics, such as the commonly used PLINK (*Purcell et al., 2007*) set-based test and software VEGAS (Versatile Gene-based Association Study) (*Liu et al., 2010*), which are permutation and simulation-based approaches respectively. Both methods rely on resampling which is computationally intensive. Here, we adopted the *fastBAT* method which was a robust set-based association (*Bakshi et al., 2016*). 431 genes located at 50 loci reached genome-wide significance in the RA dataset, including 17 known loci (*Acosta-Herrera et al., 2019; Buniello et al., 2019; Eyre et al., 2012; Plenge et al., 2005; Raychaudhuri et al., 2009; Zhu et al., 2016*) and 33 novel loci which should be examined in future replication studies (Table S4).

However only genes in the HLA region showed genome-wide significant association with JIA, which was likely due to the limited power of our previous GWAS (Table S5). A total of 75 significant genes or regions in the HLA were shared by JIA and RA (Table S6). Then we checked whether significant genes in RA contained additional genome-wide significant SNPs in JIA reported in GWAS catalog. Not surprisingly, one RA significant gene in the HLA region and 8 genes outside the HLA region containing genome-wide significant SNPs for JIA (Table 2) were observed. Because the *fastBAT* method conducted LD-pruning before combining SNP statistics, the top SNP showed in Table 2 may not be the one with the best *P*-value in original GWAS.

			RA		JIA				
SNP	Chr	Pos	Allele OR Pval		Allele	OR	Pval	RefSeq gene	
rs6679677	1	114303808	А	1.81	2.1E-149	А	1.59	3E-25	644bp 3' of <i>RSBN1</i>
rs10174238	2	191973034	G	1.14	1.2E-13	G	1.29	1E-13	STAT4
rs10213692	5	55442249	Т	1.19	1.3E-17		1.27	3E-11	ANKRD55
rs7731626	5	55444683	G	1.20	7.3E-24	A 1E-10		ANKRD55	
rs2517930	6	29745075	Т	1.18	1.7E-31	Т	1.47	8.95E-11	14kb 3' of <i>HCG</i> 4
rs2975033	6	29822261	А	1.18	1.6E-33	А	1.47	6.48E-10	23kb 3' of HLA-G
rs12206499	6	29937127	G	1.16	6.4E-26	G	1.41	3.59E-08	5.8kb 5' of <i>HCG</i> 9
rs3823355	6	29942083	Т	1.16	6.5E-26	Т	1.43	1.10E-08	807bp 5' of <i>HCG</i> 9
rs6904029	6	29943067	А	1.16	6.8E-26	А	1.43	1.44E - 08	HCG9
rs3823375	6	29944158	С	1.16	1.7E-25	С	1.44	3.10E-09	HCG9
rs9366752	6	30024677	Т	1.09	1.6E-09	Т	1.51	2.97E-10	ZNRD1-AS1
rs1265048	6	31081409	С	1.12	5.3E-17	С	1.44	2.91E-09	1.1kb 5' of C6orf15
rs13202464	6	31344583	G	1.19	1.5E-15	G	2.00	2.09E-11	20kb 5' of <i>HLA-B</i>
rs9266689	6	31348580	G	1.14	3.3E-19	G	1.54	6.16E-11	19kb 5' of MICA
rs2844533	6	31350802	А	1.30	6.6E-55	А	1.61	2.90E-08	17kb 5' of MICA
rs2261033	6	31603591	G	1.56	4.2E-183	G	1.48	5.09E-09	PRRC2A
rs6941112	6	31946614	А	1.31	6.1E-83	А	1.42	3.20E-09	STK19
rs8111	6	32083175	Т	1.33	7.2E-86	Т	1.49	5.60E-11	ATF6B
rs204999	6	32109979	А	1.55	5.5E-134	А	1.53	5.88E-09	6.2kb 3' of <i>PRRT1</i>
rs17576984	6	32212985	С	1.54	3.0E-72	Т	1.86	1.66E-12	21kb 5' of NOTCH4
rs570963	6	32289594	А	1.18	2.9E-18	G	1.70	8.91E-11	C6orf10
rs910049	6	32315727	С	1.19	5.2E-24	С	1.65	5.48E-10	C6orf10
rs2395148	6	32321554	G	1.41	1.0E-20	Т	3.62	1.08E-25	C6orf10
rs6907322	6	32324945	G	1.14	1.7E-15	А	1.69	9.99E-15	C6orf10
rs9268365	6	32333439	G	1.16	1.3E-20	Т	1.66	4.98E-14	C6orf10
rs3129941	6	32337686	G	1.64	1.4E-133	G	1.60	1.48E-09	C6orf10
rs41291794	6	32425762	А	1.65	1.1E-63		2.10	4E-15	13kb 3' of HLA-DRA
rs2395185	6	32433167	Т	2.01	1.0E-250	G	1.81	1.19E-16	20kb 3' of HLA-DRA
rs477515	6	32569691	А	1.99	1.0E-250	G	1.89	3.19E-18	12kb 5' of HLA-DRB1
rs2516049	6	32570400	С	2.00	1.0E-250	Т	1.89	2.62E-18	13kb 5' of HLA-DRB1
rs2858870	6	32572251	Т	1.86	1.1E-77	Т	2.19	8.41E-12	15kb 5' of HLA-DRB1
rs7775055	6	32657916	С	1.56	1.4E - 60	С	6.01	3E-174	23kb 5' of HLA-DQB1
rs9275224	6	32659878	G	2.13	1.0E-250	G	1.41	1.06E-08	25kb 5' of HLA-DQB1
rs6457617	6	32663851	Т	2.14	1.0E-250	Т	1.40	1.10E-08	29kb 5' of HLA-DQB1
rs2858308	6	32670000	G	1.61	7.8E-92	G	1.98	1.94E-08	36kb 5' of HLA-DQB1
rs2856705	6	32670956	С	1.61	1.0E-91	С	1.99	1.64E-08	36kb 5' of HLA-DQB1
rs13192471	6	32671103	С	1.49	4.8E-123	С	1.93	1.93E-19	37kb 5′ of <i>HLA-DQB1</i>

Table 1Genome-wide significant SNPs shared by RA and JIA (P-value < 5 × 10⁻⁸). The raw data of genome-wide significant SNPs of RA arepresented in Table S1; and the raw data of genome-wide significant SNPs of JIA are shown in Tables S2 and S3.

(continued on next page)

Table 1 (continued)

				RA JIA		_			
SNP	Chr	Pos	Allele	OR	Pval	Allele	OR	Pval	RefSeq gene
rs1794275	6	32671248	А	1.33	3.7E-69	А	1.82	3.47E-13	37kb 5′ of <i>HLA-DQB1</i>
rs7765379	6	32680928	G	1.89	1.0E - 250	G	1.68	3.11E-10	28kb 5' of <i>HLA-DQA2</i>
rs4713610	6	33107955	G	1.27	5.7E-49	G	1.54	7.54E-09	11kb 3′ of <i>HLA-DPB2</i>
rs9277912	6	33124658	Т	1.26	1.1E-48	Т	1.51	2.61E-08	5.8kb 3' of COL11A2
rs706778	10	6098949	Т	1.09	1.5E-10	Т		6E-09	IL2RA
rs9532434	13	40355913	С	1.10	1.0E-11		1.19	5E-08	COG6
rs3825568	14	69260588	Т	1.08	2.7E-08		1.30	1E-08	802bp 5' of ZFP36L1
rs2847293	18	12782448	А	1.12	1.2E-10	А	1.31	1E-12	3kb 3' of PTPN2
rs34536443	19	10463118	G	1.46	4.4E-16		1.79	1E-10	TYK2
rs8129030	21	36712588	А	1.09	2.5E-09		1.28	5E-09	291kb 5′ of <i>RUNX1</i>

Notes.

SNP, single nucleotide polymorphism; Chr, chromosome; Pos, position on human genome build hg19 (NCBI GRCh37); RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; Allele, risk allele; OR, odds ratio of risk allele; Pval, disease association P-value of risk SNP; RefSeq gene, the closest gene to each SNP and their relative positions based on Reference sequence (RefSeq) database (*O'Leary et al., 2016*).

Table 2Genome-wide significant genes outside the HLA region shared by RA and JIA (gene-based P-value < 2×10^{-6}). The raw data ofgenome-wide significant genes of RA are shown in Table S4 and those of JIA are shown in Tables S3 and S5.

			RA			JIA		
Gene	Chr	Start-End	Pval	TopSNP_Pval	TopSNP	TopSNP_Pval	TopSNP	
PHTF1	1	114239823-114301777	7.41E-43	1.7E-38	rs1217416	3E-25	rs6679677	
RSBN1	1	114304453-114355070	2.08E-19	2.8E-35	rs3811019	3E-25	rs6679677	
ANKRD55	5	55395506-55529186	2.42E-09	7.3E-24	rs7731626	3E-11	rs10213692	
IL2RA	10	6052656-6104333	4.58E-07	1.5E-10	rs706778	8E-10	rs7909519	
SUOX	12	56391042-56399309	6.95E-07	3.7E-07	rs701006	4E-09	rs1689510	
LOC100996324	18	12739484-12749421	5.76E-11	3.4E-15	rs2847297	1E-12	rs2847293	
PTPN2	18	12785476-12884334	9.99E-14	1.1E-15	rs7241016	1E-12	rs2847293	
TYK2	19	10461203-10491248	4.02E-07	2.7E-06	rs12459219	1E-10	rs34536443	

Notes.

Chr, chromosome; Start-End, start and end boundaries of the gene region on human genome build UCSC hg19 (NCBI GRCh37); RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; Pval, gene-level P-value based on fastBAT method; TopSNP, the top associated GWAS SNP; TopSNP_Pval, smallest single-SNP GWAS P-value in the gene region.

Pathway-level comparison

GWAS pathway analysis consider either competitive null hypothesis or self-contained null hypothesis. Many methods for GWAS pathway analysis have been developed, but they are still subjected to the issues of low power and being influenced by some free parameters. The recently developed GSA-SNP2 package (*Yoon et al., 2018*) uses the random set model to compute pathway enrichment with decent type I error control by integrating the gene scores adjusted by the number of SNPs mapped to each gene and removing high inter-gene correlated adjacent genes in each pathway. It does not require any key free parameters concurrently. We applied this method to our analyses. RA or JIA associated genes were enriched in numerous canonical pathways at a threshold of Q-value <0.05. A total of 32 enriched pathways were shared by RA and JIA, which mostly were immune-related pathways, such as allograft rejection, type 1 diabetes mellitus, graft versus host disease,

			RA		JIA			
Pathway	Database	Size	Count	Pval	Qval	Count	Pval	Qval
TYPE I DIABETES MELLITUS	KEGG	44	23	1.66E-07	1.58E-05	41	2.12E-05	0.001785
IL27 PATHWAY	PID	26	26	0.001158	0.027447	25	4.79E-08	8.63E-06
NO2IL12 PATHWAY	BIOCARTA	17	15	0.002316	0.047593	16	1.87E-05	0.001686

Table 3 Enriched pathways shared by RA and JIA after loci in the HLA region being removed (Q- value < 0.05).

Notes.

Pathway, abbreviation for each enriched pathway; Database, database from which the pathways were extracted; Size, total number of genes in each pathway; RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; Count, the number of RA/JIA- significant genes falling into each pathway; Pval, P-value of each pathway; Qval, Q-value of each pathway based on the trend curve adjusted gene scores.

antigen processing and presentation, autoimmune thyroid disease, asthma, etc. (Table S7). Most of these significant pathways were driven by genes in the HLA region. In order to explore the role of loci outside the HLA region for these two diseases, we performed pathway enrichment analysis again after removing loci in the HLA region based on their genomic coordinates. The HLA region was defined as chr6:28,477,797-33,448,354 (GRCh37/hg19). Pathways such as interleukin(IL)-27 pathway and NO2-dependent IL-12 pathway in natural killer (NK) cells were significantly enriched even after the HLA region loci were removed (Table 3). Global networks were visualized at a threshold of gene-score <0.005 (Figs. 1&2). We observed the common hub role of several genes such as *TYK2*. The networks before removing the HLA region were shown in Figs. S1 and S2.

DISCUSSION

Despite the phenotypic similarity between JIA and RA, systematic comparison of genetic similarity and distinction between these two types of diseases are lacking. Large scale GWASs of RA and JIA respectively render us ability to conduct such comparison and to identify potential common mechanism in disease pathogenesis, which may help repositioning and designing treatment strategies.

To systematically compare the genetic architecture of the two diseases, we performed gene-level, pathway-level analyses and conducted comparison at each level. Not only did we observe a large amount of overlaps in the HLA region as expected, but we also observed several SNPs and genes which significantly associated with both diseases outside the HLA region. Among them, the risk alleles of several SNPs were different between the two diseases, which meant that a certain allele may play a risk role in one disease but a protective role in the other. These SNPs might be related to the differences in pathogenesis and phenotype between JIA and RA. As we did not perform genome-wide imputation analysis due to unavailability of individual-level data, the number of genome-wide significant SNPs shared by these two diseases was actually underestimated.

Due to the limited sample size of our JIA data, we could not perform analysis for each subtype of JIA with enough statistical power. However, the heterogeneity of JIA and the genetic basis of its subtypes are worth noting. Some HLA alleles show different directions of effects on different subtypes of JIA and RA. For instance, HLA-DRB1*8, HLA-DRB1*11 and HLA-DRB1*13 are risk alleles of seronegative JIA, but do not exhibit



Figure 1 The global network of RA after the HLA region being removed (Q-value < 0.05, gene-score < 0.005). The PPI network was constructed among proteins encoded by the significant RA-associated genes excluding those in the HLA region. The nodes in the figure represent the proteins and the connections between nodes indicate protein-protein interactions. The size of each node suggests the degrees of the connection between the node and the others.

Full-size DOI: 10.7717/peerj.8234/fig-1

association with seropositive polyarticular JIA and seronegative RA, and these HLA alleles render protective effect for seropositive RA. In particular, DRB1*11 is also a risk allele of systemic JIA, while the other two alleles are not associated with this JIA subtype (*Nigrovic, Raychaudhuri & Thompson, 2018*). As for alleles outside the HLA region, certain SNPs in genes *PTPN22* and *STAT1/STAT4* do not show association with systemic JIA, but confer risk for most other subtypes of JIA and RA (*Nigrovic, Raychaudhuri & Thompson, 2018*). In a recent study, Hinks et al. demonstrated that RF-positive polyarticular JIA is more similar to adult RA compared to other JIA subtypes in terms of genetic profile examined



Figure 2 The global network of JIA after the HLA region being removed (Q-value < 0.05, gene-score < 0.005). The PPI network was constructed among proteins encoded by the significant JIA-associated genes excluding those in the HLA region. The nodes in the figure represent the proteins and the connections between nodes indicate protein-protein interactions. The size of each node suggests the degrees of the connection between the node and the others.

Full-size DOI: 10.7717/peerj.8234/fig-2

on Immunochip (*Hinks et al., 2018*; *Onuora, 2018*). Further analysis of the genetic nature of different subtypes of JIA and RA would be helpful to optimize the classification of the two diseases, and may lead to more effective treatment and better prognosis.

We observed significant enrichment of NO2-dependent IL12 pathway and IL27 pathway for both RA and JIA. Macrophages release IL-12 which plays an important role in activation of NK cells and induces cytotoxicity with nitric oxide (Liu et al., 2005). NK cells are regarded as a bridge between innate and adaptive immunity, serving as a key regulator in the pathogenesis and development of autoimmune diseases (Gianchecchi, Delfino & Fierabracci, 2018). It has been reported that high percentages of NK cells and their activity were found in synovial fluid of active RA patients at advanced stage (Yamin et al., 2019), and dysfunction of NK cells was also observed in patients with systemic-onset JIA and its complication (Grom et al., 2003). NO2-dependent IL12 pathway plays a unique role in the activation of NK cells by macrophage. The enrichment of this pathway in our analyses implies the potential role of abnormal IL-12-mediated activation of NK cell in the pathogenesis of RA and JIA. IL-12 has long been considered as a therapeutic target of arthritis and other autoimmune and inflammatory disorders (Hasko & Szabo, 1999; Siebert et al., 2015). As a member of the IL-12 family, IL-27 induces T cell differentiation and causes immunosuppressive effects by inhibiting the development of Th17 cells (Yoshida & Miyazaki, 2008). Previous studies have suggested that IL-27 is another key modulator of autoimmunity and elevation of IL-27 signaling may be inhibitory to some autoimmune diseases, such as multiple sclerosis or uveitis (Amadi-Obi et al., 2007). Our results suggest that such therapeutic approach may be also applied to the management of RA and JIA.

CONCLUSION

Our study identified genetic similarities and differences between RA and JIA at multiple levels. We observed a number of genes being associated with both diseases especially in the HLA region, and distinct genetic loci were found as well. Such systematic comparison and further functional characterization of these genetic loci and signaling pathways may lead to the identification of common drug targets for both diseases or drug repositioning, and may also contribute to the precision treatment of each disease.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was supported by National Natural Science Foundation of China (No.81771769), Tianjin Natural Science Foundation (No.18JCYBJC42700), Startup Funding from Tianjin Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors: National Natural Science Foundation of China: No.81771769. Tianjin Natural Science Foundation: No.18JCYBJC42700. Tianjin Medical University.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Jun Jia and Junyi Li analyzed the data, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
- Xueming Yao, YuHang Zhang, Xiaohao Yang and Ping Wang analyzed the data, prepared figures and/or tables, and approved the final draft.
- Qianghua Xia, Hakon Hakonarson and Jin Li conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

All data generated in this study are available in the Supplemental Files.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.8234#supplemental-information.

REFERENCES

- Acosta-Herrera M, Kerick M, Gonzalez-Serna D, Wijmenga C, Franke A, Gregersen PK, Padyukov L, Worthington J, Vyse TJ, Alarcon-Riquelme ME, Mayes MD, Martin J. 2019. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. *Annals of the Rheumatic Diseases* 78:311–319 DOI 10.1136/annrheumdis-2018-214127.
- Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. 2007. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. *Nature Medicine* 13:711–718 DOI 10.1038/nm1585.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthitis and Rheumatism* 31:315–324 DOI 10.1002/art.1780310302.
- Bakshi A, Zhu Z, Vinkhuyzen AAE, Hill WD, McRae AF, Visscher PM, Yang J. 2016. Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Scientific Reports* 6:32894 DOI 10.1038/srep32894.
- Behrens EM, Finkel TH, Bradfield JP, Kim CE, Linton L, Casalunovo T, Frackelton EC, Santa E, Otieno FG, Glessner JT, Chiavacci RM, Grant SF, Hakonarson H.
 2008. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. *Arthitis and Rheumatism* 58:2206–2207 DOI 10.1002/art.23603.

- Buniello A, Jacqueline A, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, Suveges D, Vrousgou O, Whetzel PL, Amode R, Guillen JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorff LA, Cunningham F, Parkinson H. 2019. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Research* 47:D1005–D1012 DOI 10.1093/nar/gky1120.
- Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, Kassoumeri L, Flynn E, Bulatovic M, Wulffraat N, Van Zelst B, De Jonge R, Bohm M, Dolezalova P, Hirani S, Newman S, Whitworth P, Southwood TR, De Iorio M, Wedderburn LR, Thomson W. 2014. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. *The Pharmacogenomics Journal* 14:356–364 DOI 10.1038/tpj.2014.3.
- De Silvestri A, Capittini C, Poddighe D, Marseglia GL, Mascaretti L, Bevilacqua E, Scotti V, Rebuffi C, Pasi A, Martinetti M, Tinelli C. 2017. HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis. *Autoimmunity Reviews* 16(12):1230–1236 DOI 10.1016/j.autrev.2017.10.007.
- Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, De Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D, Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Arlsetig L, Martin J, Rantapaa-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J. 2012. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. *Nature Genetics* 44:1336–1340 DOI 10.1038/ng.2462.
- Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. 2018. The reactome pathway knowledgebase. *Nucleic Acids Research* 46:D649–D655 DOI 10.1093/nar/gkx1132.
- Finkel TH, Li J, Wei Z, Wang W, Zhang H, Behrens EM, Reuschel EL, Limou S, Wise C, Punaro M, Becker ML, Munro JE, Flato B, Forre O, Thompson SD, Langefeld CD, Glass DN, Glessner JT, Kim CE, Frackelton E, Shivers DK, Thomas KA, Chiavacci RM, Hou C, Xu K, Snyder J, Qiu H, Mentch F, Wang K, Winkler CA, Lie BA, Ellis JA, Hakonarson H. 2016. Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility. *BMC Medical Genetics* 17:24 DOI 10.1186/s12881-016-0285-3.
- **Firestein GS. 2003.** Evolving concepts of rheumatoid arthritis. *Nature* **423**:356–361 DOI 10.1038/nature01661.
- Firestein GS, McInnes IB. 2017. Immunopathogenesis of Rheumatoid Arthritis. *Immunity* 46:183–196 DOI 10.1016/j.immuni.2017.02.006.

- Gianchecchi E, Delfino DV, Fierabracci A. 2018. NK cells in autoimmune diseases: linking innate and adaptive immune responses. *Autoimmunity Reviews* 17:142–154 DOI 10.1016/j.autrev.2017.11.018.
- **Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. 2003.** Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. *Jornal de Pediatria* **142**:292–296 DOI 10.1067/mpd.2003.110.
- Hasko G, Szabo C. 1999. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. *British Journal of Pharmacology* 127:1295–1304 DOI 10.1038/sj.bjp.0702689.
- Hersh AO, Prahalad S. 2015. Immunogenetics of juvenile idiopathic arthritis: a comprehensive review. *Journal of Autoimmunity* 64:113–124 DOI 10.1016/j.jaut.2015.08.002.
- Hinks A, Barton A, Shephard N, Eyre S, Bowes J, Cargill M, Wang E, Ke X, Kennedy GC, John S, Worthington J, Thomson W. 2009. Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. *Arthtitis and Rheumatism* 60:258–263 DOI 10.1002/art.24179.
- Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, Martin P, Comeau ME, Sajuthi S, Andrews R, Brown M, Chen WM, Concannon P, Deloukas P, Edkins S, Eyre S, Gaffney PM, Guthery SL, Guthridge JM, Hunt SE, James JA, Keddache M, Moser KL, Nigrovic PA, Onengut-Gumuscu S, Onslow ML, Rose CD, Rich SS, Steel KJ, Wakeland EK, Wallace CA, Wedderburn LR, Woo P, Bohnsack JF, Haas JP, Glass DN, Langefeld CD, Thomson W, Thompson SD. 2013. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. *Nature Genetics* 45:664–669 DOI 10.1038/ng.2614.
- Hinks A, Marion MC, Cobb J, Comeau ME, Sudman M, Ainsworth HC, Bowes J, Immunochip JIACF, Becker ML, Bohnsack JF, Haas J-P, Lovell DJ, Mellins ED, Nelson JL, Nordal E, Punaro M, Reed AM, Rose CD, Rosenberg AM, Rygg M, Smith SL, Stevens AM, Videm V, Wallace CA, Wedderburn LR, Yarwood A, Yeung RSM, Langefeld CD, Thompson SD, Thomson W, Prahalad S. 2018. Brief report: the genetic profile of rheumatoid factor—positive polyarticular juvenile idiopathic arthritis resembles that of adult rheumatoid arthritis. *Arthritis & Rheumatology* 70:957–962 DOI 10.1002/art.40443.
- Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. 2017. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. *Rheumatology International* 37:1551–1557 DOI 10.1007/s00296-017-3726-1.
- Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. 2017. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Research* 45:D353–D361 DOI 10.1093/nar/gkw1092.
- Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Research* 28:27–30 DOI 10.1093/nar/28.1.27.

- Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. 2019. New approach for understanding genome variations in KEGG. *Nucleic Acids Research* 47:D590—D595 DOI 10.1093/nar/gky962.
- Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, Hou C, Abrams DJ, Chang D, Gao F, Guo Y, Wei Z, Connolly JJ, Cardinale CJ, Bakay M, Glessner JT, Li D, Kao C, Thomas KA, Qiu H, Chiavacci RM, Kim CE, Wang F, Snyder J, Richie MD, Flato B, Forre O, Denson LA, Thompson SD, Becker ML, Guthery SL, Latiano A, Perez E, Resnick E, Russell RK, Wilson DC, Silverberg MS, Annese V, Lie BA, Punaro M, Dubinsky MC, Monos DS, Strisciuglio C, Staiano A, Miele E, Kugathasan S, Ellis JA, Munro JE, Sullivan KE, Wise CA, Chapel H, Cunningham-Rundles C, Grant SF, Orange JS, Sleiman PM, Behrens EM, Griffiths AM, Satsangi J, Finkel TH, Keinan A, Prak ET, Polychronakos C, Baldassano RN, Li H, Keating BJ, Hakonarson H. 2015a. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. *Nature Medicine* 21:1018–1027 DOI 10.1038/nm.3933.
- Li YR, Zhao SD, Li J, Bradfield JP, Mohebnasab M, Steel L, Kobie J, Abrams DJ, Mentch FD, Glessner JT, Guo Y, Wei Z, Connolly JJ, Cardinale CJ, Bakay M, Li D, Mag-gadottir SM, Thomas KA, Qui H, Chiavacci RM, Kim CE, Wang F, Snyder J, Flato B, Forre O, Denson LA, Thompson SD, Becker ML, Guthery SL, Latiano A, Perez E, Resnick E, Strisciuglio C, Staiano A, Miele E, Silverberg MS, Lie BA, Punaro M, Russell RK, Wilson DC, Dubinsky MC, Monos DS, Annese V, Munro JE, Wise C, Chapel H, Cunningham-Rundles C, Orange JS, Behrens EM, Sullivan KE, Kugathasan S, Griffiths AM, Satsangi J, Grant SF, Sleiman PM, Finkel TH, Polychronakos C, Baldassano RN, Prak Luning ET, Ellis JA, Li H, Keating BJ, Hakonarson H. 2015b. Genetic sharing and heritability of paediatric age of onset autoimmune diseases. *Nature Communications* 6:Article 8442 DOI 10.1038/ncomms9442.
- Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov Jill P, Tamayo P. 2015. The molecular signatures database hallmark gene set collection. *Cell Systems* 1:417–425 DOI 10.1016/j.cels.2015.12.004.
- Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27:1739–1740 DOI 10.1093/bioinformatics/btr260.
- Liu J, Cao S, Kim S, Chung EY, Homma Y, Guan X, Jimenez V, Ma X. 2005. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. *Current Immunology Reviews* 1:119–137 DOI 10.2174/1573395054065115.
- Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, Investigators A, Hayward NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S. 2010. A versatile gene-based test for genome-wide association studies. *American Journal of Human Genetics* 87:139–145 DOI 10.1016/j.ajhg.2010.06.009.
- Macgregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ. 2000. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis & Rheumatism* **43**:30–37.

- Mellins ED, Macaubas C, Grom AA. 2011. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. *Nature Reviews Rheumatology* 7:416–426 DOI 10.1038/nrrheum.2011.68.
- Nigrovic PA, Raychaudhuri S, Thompson SD. 2018. Review: genetics and the classification of arthritis in adults and children. *Arthritis & Rheumatology* 70:7–17 DOI 10.1002/art.40350.
- Nishimura D. 2001. BioCarta. *Biotech Software & Internet Report* 2:117–120 DOI 10.1089/152791601750294344.
- Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, Van Riel PL, Van de Laar MA, Guchelaar HJ, Huizinga TW, Dieude P, Mariette X, Bridges Jr SL, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapaa-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M, Eyre S, Bowes J, Barton A, De Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. 2014. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376-381 DOI 10.1038/nature12873.
- O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B, Robbertse B, Smith-White B, Ako-Adjei D, Astashyn A, Badretdin A, Bao Y, Blinkova O, Brover V, Chetvernin V, Choi J, Cox E, Ermolaeva O, Farrell CM, Goldfarb T, Gupta T, Haft D, Hatcher E, Hlavina W, Joardar VS, Kodali VK, Li W, Maglott D, Masterson P, McGarvey KM, Murphy MR, O'Neill K, Pujar S, Rangwala SH, Rausch D, Riddick LD, Schoch C, Shkeda A, Storz SS, Sun H, Thibaud-Nissen F, Tolstoy I, Tully RE, Vatsan AR, Wallin C, Webb D, Wu W, Landrum MJ, Kimchi A, Tatusova T, DiCuccio M, Kitts P, Murphy TD, Pruitt KD. 2016. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Research* 44(D1):D733–D745 DOI 10.1093/nar/gkv1189.
- Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Ozen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcon-Riquelme ME, Docampo E, Estivill X, Gul A, Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W. 2017. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis:

clinical and therapeutic implications. *Annals of the Rheumatic Diseases* **76**:906–913 DOI 10.1136/annrheumdis-2016-210324.

- **Onuora S. 2018.** Genetics: subtype of JIA is genetically similar to adult RA. *Nature Reviews Rheumatology* **14**:181–181 DOI 10.1038/nrrheum.2018.30.
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P.
 2004. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *Journal of Rheumatology* 31:390–392.
- Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD. 2005.
 Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. *American Journal of Human Genetics* 77:1044–1060 DOI 10.1086/498651.
- **Prahalad S. 2006.** Genetic analysis of juvenile rheumatoid arthritis: approaches to complex traits. *Current Problems in Pediatric and Adolescent Health Care* **36(3)**:83–90 DOI 10.1016/j.cppeds.2005.10.009.
- **Prakken B, Albani S, Martini A. 2011.** Juvenile idiopathic arthritis. *The Lancet* **377**:2138–2149 DOI 10.1016/s0140-6736(11)60244-4.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De Bakker PI, Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics* 81:559–575 DOI 10.1086/519795.
- **Ravelli A, Martini A. 2007.** Juvenile idiopathic arthritis. *The Lancet* **369**:767–778 DOI 10.1016/S0140-6736(07)60363-8.
- Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Burtt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Kurreeman FA, Lee AT, Liu X, Li Y, Martin P, Morgan AW, Padyukov L, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, Van der Helm-van Mil AH, Van der Horst-Bruinsma IE, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P, Altshuler D, Karlson EW, Toes RE, De Vries N, Begovich AB, Siminovitch KA, Worthington J, Klareskog L, Gregersen PK, Daly MJ, Plenge RM. 2009. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. *Nature Genetics* 41:1313–1318 DOI 10.1038/ng.479.
- Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. 2009. PID: the pathway interaction database. *Nucleic Acids Research* **37**:D674–D679 DOI 10.1093/nar/gkn653.
- Scott DL, Wolfe F, Huizinga TW. 2010. Rheumatoid arthritis. *Lancet* 376:1094–1108 DOI 10.1016/s0140-6736(10)60826-4.

- Siebert S, Tsoukas A, Robertson J, McInnes I. 2015. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. *Pharmacological Reviews* 67:280–309 DOI 10.1124/pr.114.009639.
- **Speed D, Balding DJ. 2014.** MultiBLUP: improved SNP-based prediction for complex traits. *Genome Research* **24**:1550–1557 DOI 10.1101/gr.169375.113.
- **Speed D, Hemani G, Johnson MR, Balding DJ. 2012.** Improved heritability estimation from genome-wide SNPs. *American Journal of Human Genetics* **91**:1011–1021 DOI 10.1016/j.ajhg.2012.10.010.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America* 102:15545–15550 DOI 10.1073/pnas.0506580102.
- Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, Von Mering C. 2015. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Research* 43:D447–D452 DOI 10.1093/nar/gku1003.
- The Genomes Project Consortium, Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE, Flicek P, Gabriel SB, Gibbs RA, Green ED, Hurles ME, Knoppers BM, Korbel JO, Lander ES, Lee C, Lehrach H, Mardis ER, Marth GT, McVean GA, Nickerson DA, Schmidt JP, Sherry ST, Wang J, Wilson RK, Gibbs RA, Boerwinkle E, Doddapaneni H, Han Y, Korchina V, Kovar C, Lee S, Muzny D, Reid JG, Zhu Y, Wang J, Chang Y, Feng Q, Fang X, Guo X, Jian M, Jiang H, Jin X, Lan T, Li G, Li J, Li Y, Liu S, Liu X, Lu Y, Ma X, Tang M, Wang B, Wang G, Wu H, Wu R, Xu X, Yin Y, Zhang D, Zhang W, Zhao J, Zhao M, Zheng X, Lander ES, Altshuler DM, Gabriel SB, Gupta N, Gharani N, Toji LH, Gerry NP, Resch AM, Flicek P, Barker J, Clarke L, Gil L, Hunt SE, Kelman G, Kulesha E, Leinonen R, McLaren WM, Radhakrishnan R, Roa A, Smirnov D, Smith RE, Streeter I, Thormann A, Toneva I, Vaughan B, Zheng-Bradley X, Bentley DR, Grocock R, Humphray S, James T, Kingsbury Z, Lehrach H, Sudbrak R, Albrecht MW, Amstislavskiy VS, Borodina TA, Lienhard M, Mertes F, Sultan M, Timmermann B, Yaspo M-L, Mardis ER, Wilson RK, Fulton L, Fulton R, Sherry ST, Ananiev V, Belaia Z, Beloslyudtsev D, Bouk N, Chen C, Church D, Cohen R, Cook C, Garner J, Hefferon T, Kimelman M, Liu C, Lopez J, Meric P, O'Sullivan C, Ostapchuk Y, Phan L, Ponomarov S, Schneider V, Shekhtman E, Sirotkin K, Slotta D, Zhang H, McVean GA, Durbin RM, Balasubramaniam S, Burton J, Danecek P, Keane TM, Kolb-Kokocinski A, McCarthy S, Stalker J, Quail M, Schmidt JP, Davies CJ, Gollub J, Webster T, Wong B, Zhan Y, Auton A, Campbell CL, Kong Y, Marcketta A, Gibbs RA, Yu F, Antunes L, Bainbridge M, Muzny D, Sabo A, Huang Z, Wang J, Coin LJM, Fang L, Guo X, Jin X, Li G, Li Q, Li Y, Li Z, Lin H, Liu B, Luo R, Shao H, Xie Y, Ye C, Yu C, Zhang F, Zheng H, Zhu H, Alkan C, Dal E, Kahveci F, Marth GT, Garrison EP, Kural D, Lee W-P, Leong WFung, Stromberg M, Ward AN, Wu J, Zhang M, Daly MJ, DePristo MA, Handsaker RE, Altshuler DM, Banks

E, Bhatia G, Del Angel G, Gabriel SB. 2015. A global reference for human genetic variation. *Nature* **526**:68–74 DOI 10.1038/nature15393.

- Thierry S, Fautrel B, Lemelle I, Guillemin F. 2014. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. *Joint Bone Spine* 81:112–117 DOI 10.1016/j.jbspin.2013.09.003.
- Thompson SD, Marion MC, Sudman M, Ryan M, Tsoras M, Howard TD, Barnes MG, Ramos PS, Thomson W, Hinks A, Haas JP, Prahalad S, Bohnsack JF, Wise CA, Punaro M, Rose CD, Pajewski NM, Spigarelli M, Keddache M, Wagner M, Langefeld CD, Glass DN. 2012. Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. *Arthitis and Rheumatism* 64:2781–2791 DOI 10.1002/art.34429.
- Viatte S, Plant D, Raychaudhuri S. 2013. Genetics and epigenetics of rheumatoid arthritis. *Nature Reviews Rheumatology* 9:141–153 DOI 10.1038/nrrheum.2012.237.
- Yamin R, Berhani O, Peleg H, Aamar S, Stein N, Gamliel M, Hindi I, Scheiman-Elazary A, Gur C. 2019. High percentages and activity of synovial fluid NK cells present in patients with advanced stage active Rheumatoid Arthritis. *Scientific Reports* 9:1351 DOI 10.1038/s41598-018-37448-z.
- Yang J, Lee SH, Goddard ME, Visscher PM. 2011. GCTA: a tool for genome-wide complex trait analysis. *The American Journal of Human Genetics* 88:76–82 DOI 10.1016/j.ajhg.2010.11.011.
- Yoon S, Nguyen HCT, Yoo YJ, Kim J, Baik B, Kim S, Kim J, Kim S, Nam D. 2018. Efficient pathway enrichment and network analysis of GWAS summary data using GSA-SNP2. *Nucleic Acids Research* **46**:e60 DOI 10.1093/nar/gky175.
- Yoshida H, Miyazaki Y. 2008. Regulation of immune responses by interleukin-27. *Immunological Reviews* 226:234–247 DOI 10.1111/j.1600-065X.2008.00710.x.
- Zhu H, Xia W, Mo XB, Lin X, Qiu YH, Yi NJ, Zhang YH, Deng FY, Lei SF. 2016. Gene-based genome-wide association analysis in European and Asian populations identified novel genes for rheumatoid arthritis. *PLOS ONE* 11:e0167212 DOI 10.1371/journal.pone.0167212.